Attached files

file filename
EX-5.1 - EX-5.1 - ACCELERON PHARMA INCa2216733zex-5_1.htm
EX-23.1 - EX-23.1 - ACCELERON PHARMA INCa2216733zex-23_1.htm

QuickLinks -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on September 18, 2013

Registration No. 333-            

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM S-1

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933



ACCELERON PHARMA INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
  2836
(Primary Standard Industrial
Classification Code Number)
  27-0072226
(I.R.S. Employer
Identification Number)

128 Sidney Street
Cambridge, MA 02139
(617) 649-9200

(Address, including zip code, and telephone number, including
area code, of registrant's principal executive offices)



John L. Knopf, Ph.D.
Chief Executive Officer and President
128 Sidney Street
Cambridge, MA 02139
(617) 649-9200

(Name, address, including zip code, and telephone number, including
area code, of agent for service)



Copies to:

Marc Rubenstein, Esq.
Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, MA 02199
(617) 951-7000

 

John D. Quisel, Ph.D., Esq.
Vice President,
General Counsel and Secretary
Acceleron Pharma Inc.
128 Sidney Street
Cambridge, MA 02139
(617) 649-9200

 

Jonathan L. Kravetz, Esq.
Brian P. Keane, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.
One Financial Center
Boston, MA 02111
(617) 542-6000



Approximate date of commencement of proposed sale to public:
As soon as practicable after this Registration Statement is declared effective.

          If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.    o

          If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    ý 333-190417

          If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    o

          If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    o

          Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o   Accelerated filer o   Non-accelerated filer ý
(Do not check if a
smaller reporting company)
  Smaller reporting company o

CALCULATION OF REGISTRATION FEE

               
 
Title of each class of
securities to be registered

  Amount
to be
registered(1)

  Proposed maximum
aggregate offering
price per share

  Proposed maximum
aggregate
offering price

  Amount of
registration fee(2)

 

Common Stock, $0.001 par value

  1,069,500   $15.00   $16,042,500   $2,189

 

(1)
Represents only the additional number of shares being registered and includes 139,500 shares of common stock issuable upon exercise of the underwriters' option to purchase additional shares. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-190417).

(2)
The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities at an aggregate offering price not to exceed $80,212,500 on a Registration Statement on Form S-1 (File No. 333-190417), which was declared effective by the Securities and Exchange Commission on September 18, 2013. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $16,042,500 is hereby registered, which includes shares issuable upon the exercise of the underwriters' option to purchase additional shares.

          The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

   



Explanatory note and incorporation by reference

        This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"). The contents of the Registration Statement on Form S-1 (File No. 333-190417) filed by Acceleron Pharma Inc. with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act, which was declared effective by the Commission on September 18, 2013, are incorporated by reference into this Registration Statement.

        The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.



Signatures

        Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts, on September 18th, 2013.

    ACCELERON PHARMA INC.

 

 

By:

 

/s/ JOHN KNOPF, PH.D.

John L. Knopf, Ph.D.
Chief Executive Officer and President

Signatures

        Pursuant to the requirements of the Securities Act, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

Signature
 
Title
 
Date

 

 

 

 

 
/s/ JOHN KNOPF, PH.D.

John L. Knopf, Ph.D.
  Chief Executive Officer and President (Principal Executive Officer)   September 18, 2013

*

Kevin F. McLaughlin

 

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

September 18, 2013

*

Anthony B. Evnin, Ph.D.

 

Director

 

September 18, 2013

*

Jean M. George

 

Director

 

September 18, 2013

*

George Golumbeski, Ph.D.

 

Director

 

September 18, 2013

*

Carl L. Gordon, Ph.D., CFA

 

Director

 

September 18, 2013

Signature
 
Title
 
Date

 

 

 

 

 
*

Edwin M. Kania, Jr.
  Director   September 18, 2013

*

Tom Maniatis, Ph.D.

 

Director

 

September 18, 2013

*

Terrance G. McGuire

 

Director

 

September 18, 2013

*

Richard F. Pops

 

Director

 

September 18, 2013

*

Joseph S. Zakrzewski

 

Director

 

September 18, 2013

 

*by:   /s/ JOHN KNOPF, PH.D.

Attorney-in-Fact
       

Exhibit Number
  Description of Exhibit
  5.1   Opinion of Ropes & Gray LLP

 

23.1

 

Consent of Ernst & Young LLP

 

23.2

 

Consent of Ropes & Gray LLP (included in Exhibit 5.1)

 

24.1

*

Power of Attorney

*
Previously filed on the signature page to the Registrant's Registration Statement on Form S-1, as amended (File no. 333-190417), originally filed with the Securities and Exchange Commission on August 7, 2013 and incorporated by reference herein.



QuickLinks

Explanatory note and incorporation by reference
Signatures